Merck (MRK) Tops Q1 EPS by 31c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Merck Announces First-Quarter 2022 Financial Results
April 28, 2022 6:30 AM EDTFirst-Quarter 2022 Results Reflect Sustained Strong Business Momentum, With Robust Top- and Bottom-Line Growth First-Quarter 2022 Worldwide Sales From Continuing Operations Were $15.9 Billion, an Increase of 50% From First-Quarter 2021; LAGEVRIO Sales Were $3.2 Billion, Growth Excluding LAGEVRIO Was 19%; Sales Growth Favorably Impacted by COVID-19 Recovery KEYTRUDA Sales Grew 23% to $4.8 Billion; Excluding the Impact From Foreign Exchange, Sales Grew 27% GARDASIL and GARDASIL 9 Sales Grew 59% to $1.5 Billion; Excluding the Impact From Foreign Exchange, Sales Grew 60% Animal Health Sales Grew 4% to $1.5 Billion; Excluding the Impact From Foreign Exchange, Sales Grew 9% First-Quarter 2022 GAAP EPS From Continuing Operations Was... More
